TCGA-A7-A425-01A-11R-A24H-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 15
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.350
- WNT_BETA_CATENIN_SIGNALING+0.260
- COAGULATION+0.250
- XENOBIOTIC_METABOLISM+0.240
- KRAS_SIGNALING_DN+0.190
- APICAL_JUNCTION+0.170
- ESTROGEN_RESPONSE_EARLY+0.150
- P53_PATHWAY+0.150
- APICAL_SURFACE+0.130
- FATTY_ACID_METABOLISM+0.130
Top 10 suppressed
- PROTEIN_SECRETION-0.540
- MYC_TARGETS_V1-0.470
- MTORC1_SIGNALING-0.450
- INTERFERON_ALPHA_RESPONSE-0.400
- G2M_CHECKPOINT-0.350
- ANDROGEN_RESPONSE-0.330
- INTERFERON_GAMMA_RESPONSE-0.330
- E2F_TARGETS-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.290
- UV_RESPONSE_DN-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1IF-01A-11R-A144-07 | — | A | 0.869 |
| 2 | TCGA-BH-A42V-01A-11R-A24H-07 | — | A | 0.844 |
| 3 | TCGA-A2-A0CK-01A-11R-A22K-07 | — | A | 0.835 |
| 4 | TCGA-B6-A401-01A-11R-A239-07 | — | B | 0.832 |
| 5 | SRR1516073 | — | — | 0.828 |
| 6 | d93b1580-c20d-4611-ac99-c0cb33f37a45 | — | — | 0.818 |
| 7 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.808 |
| 8 | R37 | — | — | 0.808 |
| 9 | SJEPD028_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.807 |
| 10 | SRR5903552 | — | cohortA1 | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |